Project Grant R01CE003689
Award Date
9/30/24
Completion Date
9/29/27
Dollars Obligated
$1.7M
Funding Federal Agency
National Center for Injury Prevention and Control
Awarding Federal Agency
Office of Financial Resources
Federal Grant Program
93.136
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This $6,439,263 federal Project Grant awarded by the National Institute on Drug Abuse (CFDA 93.279 Drug Abuse and Addiction Research Programs) aims to determine the impact of maternal substance use on maternal immune activation, placental function, and offspring neurobehavioral development. The project will leverage the Healthy Brain and Child Development (HBCD) study to perform maternal immune profiling, placental and cord blood analysis, and novel neuroinflammation imaging on 400 pregnancies...
The National Institute on Drug Abuse (NIDA) awarded a $707,647 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Weill Medical College of Cornell University to conduct research on universal hepatitis C virus (HCV) screening during pregnancy. The project aims to: 1) determine if revised HCV testing guidelines led to increased testing rates among pregnant women compared to non-pregnant women; 2) assess if the guidelines increased postpartum HCV linkage to care, treatment,...
The National Institute on Drug Abuse (NIDA) awarded a Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) totaling $1,499,606.00 to the Dartmouth-Hitchcock Clinic, doing business as Dartmouth-Hitchcock Obligated Group, with a project period from September 30, 2024 to July 31, 2029. The goal of this project is to characterize health outcomes from birth to 5 years of age in children born to individuals with opioid use disorder, identify disparities across populations,...
This federal Project Grant award of $840,425.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research examining the impact of prenatal and postnatal substance exposure on adolescent risk behaviors. The award to The Pennsylvania State University will leverage a longitudinal sample of 247 families to investigate developmental cascades linking pre- and post-natal substance use risks to adolescent substance use,...
This $196,236 Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to investigate the mechanisms contributing to preconceptions about individuals who use cannabis, especially during pregnancy. The central hypothesis is that these preconceptions result in negative interactions between patients and clinicians, reducing the quality of healthcare and leading to poor outcomes. The research aims to:...
The National Institute on Drug Abuse (NIDA) awarded Magee-Womens Research Institute and Foundation a $3,092,159 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to conduct a multimodal analysis of gestational health and placental injury in opioid-affected pregnancies. The goal is to investigate the direct impact of illicit and prescription opioids on placental development, differentiation, and function, focusing on the critical syncytiotrophoblast and...
This Project Grant award, provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under CFDA Program 93.865 - Child Health and Human Development Extramural Research, will support research to estimate the impact of recent state-level reproductive and pregnancy health policy changes, such as the Dobbs v. Jackson Supreme Court decision, on fertility, maternal health, and infant health outcomes over time and across subgroups in the U.S. The $713,558...
This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) totaling $945,397 provides funding to the Magee-Womens Research Institute and Foundation, with a sub-award to the University of Pittsburgh, to adapt and evaluate a collaborative care model (CCM) for treating pregnant persons with opioid use disorder (OUD) in low-resource obstetric settings. The key objectives are to: 1) adapt the CCM for rural and low-resource...
The National Institutes of Health (NIH) awarded Boston Medical Center Corporation a $2,573,346 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The 3-year grant, which commenced on September 1, 2023, will fund a prospective cohort study comparing 100 opioid-exposed pregnancies to 50 non-exposed controls. The study aims to: Compare serial microRNA (miRNA) signatures in opioid-exposed and control pregnancies using maternal plasma and placental tissue samples. The...
The National Institute on Drug Abuse (NIDA) awarded The Washington University a 3-year, $2,337,729 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to study the impact of prenatal opioid exposure on placental and fetal brain development. The project, titled "The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta" (OPIOID BPP), aims to define the longitudinal effects of prenatal opioid exposure on...